Future triple agonists targeting GLP-1, GIP, and glucagon receptors simultaneously are in late-stage development at multiple companies and could potentially offer additional efficacy advantages over semaglutide by the late 2020s
GLP-1 enhances insulin secretion from the pancreas, reduces hunger, and increases the feeling of fullness by delaying gastric emptying
This selective mechanism means the peptide can promote fat metabolism without affecting glucose regulation, insulin sensitivity, or cell proliferation
Thus, glutathione-mediated preservation of mitochondrial function, in our opinion, became possible due to the reduction of ROS and restoration in mitochondria of the synthesis of gas mediatorsNO and H 2 S which are important natural regulators of mPTP
Significance The findings reinforce the rising concern about the risk of vision impairment and semaglutide use